ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Aggressive Glioblastoma Cells Enhance the Migratory Persistence and Velocity of Less Aggressive Cells to Promote Tumor Dissemination.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Computer-Aided Discovery of EGFR G-Quadruplex Targeting Phenanthroimidazole Derivatives Inducing Concurrent Multi-Organelle Damage in Glioblastoma.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Glioblastoma multiforme (GBM) is a highly lethal brain cancer driven by aggressive invasion. Epidermal growth factor receptor (EGFR) is frequently amplified in GBM, with the EGFRvIII mutant enhancing the infiltrative features of EGFRwt-overexpressing cells. Previously, we identified Src as a key cell-cell communication mediator between EGFRvIII and EGFRwt cells. However, a quantitative biophysical characterization of how EGFRvIII induces this increased infiltration, specifically detailing altered movement parameters and the underlying mechanisms, remains lacking. Using bulk cell culture and 2-cell microfluidic chips, we quantitatively analyzed the motility of EGFRwt-overexpressing and EGFRvIII-expressing GBM cells. We observed that EGFRvIII cells exhibit higher migration velocity and persistence compared to EGFRwt cells, with a highly persistent subpopulation contributing significantly to these differences. Notably, the co-culture of EGFRvIII cells enhanced the velocity and migration persistence of EGFRwt-overexpressing cells, leading to increased spreading. Our findings revealed that Src-mediated cell-cell communication from EGFRvIII-expressing to EGFRwt-overexpressing cells promotes aggressive GBM spreading by increasing both their velocity and migration persistence at the micro-environmental level. Inhibiting the Src pathway with dasatinib reversed this pro-migratory effect, markedly reducing their migration persistence. These insights refine our understanding of GBM infiltration and highlight Src inhibition as a promising strategy in EGFRvIII-positive tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.